Abstract:Objectives This study was designed to assess the clinical course and to identify risk factors for life-threatening events in patients with long-QT syndrome (LQTS) with normal corrected QT (QTc) intervals.Background Current data regarding the outcome of patients with concealed LQTS are limited.Methods Clinical and genetic risk factors for aborted cardiac arrest (ACA) or sudden cardiac death (SCD) from birth through age 40 years were examined in 3,386 genotyped subjects from 7 multinational LQTS registries, categorized as LQTS with normal-range QTc (<= 440 ms [n = 469]), LQTS with prolonged QTc interval (>440 ms [ n = 1,392]), and unaffected family members (genotyped negative with <= 440 ms [ n = 1,525]).Results The cumulative probability of ACA or SCD in patients with LQTS with normal-range QTc intervals (4%) was significantly lower than in those with prolonged QTc intervals (15%) (p < 0.001) but higher than in unaffected family members (0.4%) (p < 0.001). Risk factors ACA or SCD in patients with normal-range QTc intervals included mutation characteristics (transmembrane-missense vs. nontransmembrane or nonmissense mutations: hazard ratio: 6.32; p = 0.006) and the LQTS genotypes (LQTS type 1: LQTS type 2, hazard ratio: 9.88; p = 0.03; LQTS type 3: LQTS type 2, hazard ratio: 8.04; p = 0.07), whereas clinical factors, including sex and QTc duration, were associated with a significant increase in the risk for ACA or SCD only in patients with prolonged QTc intervals (female age >13 years, hazard ratio: 1.90; p = 0.002; QTc duration, 8% risk increase per 10-ms increment; p = 0.002).Conclusions Genotype-confirmed patients with concealed LQTS make up about 25% of the at-risk LQTS population. Genetic data, including information regarding mutation characteristics and the LQTS genotype, identify increased risk for ACA or SCD in this overall lower risk LQTS subgroup. (J Am Coll Cardiol 2011;57:51-9) (C) 2011 by the American College of Cardiology Foundation

Prevention,management and Emergency Treatment of Children with Long QT Interval Syndrome and Its Advanced Torsades De Pointes

[Clinical Practice Guidelines for Long Q-T Interval Syndrome].

Current Concepts in the Management of Long QT Syndrome

Genetics, Molecular Mechanisms and Management of Long QT Syndrome

From genes to clinical management: A comprehensive review of long QT syndrome pathogenesis and treatment

Diagnosis and Treatment of Drug Induced Acquired Long QT Syndrome

Torsades De Pointes Electrical Storm in Children with KCNH2 Mutations

Lifestyle Modification and Medical Treatment of Long QT Syndrome

Prevention of Torsade de Pointes in Hospital Settings

The characteristics of electrocardiographic Tpeak-end and Tp-e/QT in the patients with long QT syndrome

The Molecular Basis of Long QT Syndrome and Prospects for Therapy.

Clinical Advances in Congenital Long QT Syndrome

Long QT Syndrome in Adults

Risk for Life-Threatening Cardiac Events in Patients with Genotype-Confirmed Long-Qt Syndrome and Normal-Range Corrected QT Intervals.

Mutations In Cytoplasmic Loops Of The Kcnq1 Channel And The Risk Of Life-Threatening Events Implications For Mutation-Specific Response To Beta-Blocker Therapy In Type 1 Long-Qt Syndrome

Clinical Aspects of Type-1 Long-Qt Syndrome by Location, Coding Type, and Biophysical Function of Mutations Involving the KCNQ1 Gene.

Diagnosis, management and therapeutic strategies for congenital long QT syndrome

The Advance on the Prenatal Diagnosis and Management of Fetal Long QT Syndrome

[QT Interval and Its Prolongation - What Does It Mean?]

Initiation of ventricular arrhythmia in the acquired long QT syndrome

Mechanisms underlying arrhythmogenesis in long QT syndrome